AN2 Therapeutics Inc Market Cap ($157.74 Million)
Market Cap & Net Worth: AN2 Therapeutics Inc (ANTX)
AN2 Therapeutics Inc market cap. AN2 Therapeutics Inc (NASDAQ:ANTX) has a market capitalization of $157.74 Million ($157.74 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #17267 globally and #4107 in its home market, demonstrating a 15.15% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying AN2 Therapeutics Inc's stock price $4.18 by its total outstanding shares 37736237 (37.74 Million). Also see how efficiently does AN2 Therapeutics Inc generate cash for how efficiently the company converts equity into cash flow.
AN2 Therapeutics Inc Market Cap History (2022–2026)
AN2 Therapeutics Inc market cap history from 2022 to 2026. Data shows change from $359.63 Million to $157.74 Million (-24.62% CAGR). Check AN2 Therapeutics Inc stock quote for real-time trading data and today's change.
Index Memberships
AN2 Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.01% | #471 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #1687 of 3165 |
Weight: AN2 Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
AN2 Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how AN2 Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore AN2 Therapeutics Inc (ANTX) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ANTX by Market Capitalization
Companies near AN2 Therapeutics Inc in the global market cap rankings as of November 5, 2026. Also see balance sheet size of AN2 Therapeutics Inc for a full breakdown of the balance sheet.
Key companies related to AN2 Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of AN2 Therapeutics Inc (2022–2026)
Market capitalization of AN2 Therapeutics Inc from 2022 to today. Between 2022 and today, AN2 Therapeutics Inc's market cap moved from $359.63 Million to $ 157.74 Million, with a yearly change of -24.62%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $157.74 Million | +266.67% |
| 2025 | $43.02 Million | -17.39% |
| 2024 | $52.08 Million | -93.27% |
| 2023 | $773.22 Million | +115.01% |
| 2022 | $359.63 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of AN2 Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $157.74 Million USD |
| MoneyControl | $157.74 Million USD |
| MarketWatch | $157.74 Million USD |
| marketcap.company | $157.74 Million USD |
| Reuters | $157.74 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About AN2 Therapeutics Inc
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15… Read more